Visirna Therapeutics Hk Limited
Clinical trials sponsored by Visirna Therapeutics Hk Limited, explained in plain language.
-
New drug aims to slash Sky-High cholesterol in rare genetic disease
Disease control OngoingThis phase 3 trial tests VSA003, an RNAi drug that targets a protein called ANGPTL3, in 46 Chinese adolescents and adults with homozygous familial hypercholesterolemia (HoFH), a genetic condition causing extremely high cholesterol. Participants receive either VSA003 or a placebo …
Phase: PHASE3 • Sponsor: Visirna Therapeutics HK Limited • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New RNA drug aims to reverse liver damage in NASH patients
Disease control OngoingThis phase 2 trial is testing an experimental drug called VSA006 in 48 Chinese adults with NASH, a type of fatty liver disease that can lead to cirrhosis. VSA006 is an RNA-based drug designed to lower a liver protein linked to disease progression. The study compares VSA006 inject…
Phase: PHASE2 • Sponsor: Visirna Therapeutics HK Limited • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC